CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:An approach to p32/gC1qR/HABP1: a multifunctional protein with an essential role in cancer.
An approach to p32/gC1qR/HABP1: a multifunctional protein with an essential role in cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
p32/gC1qR/HABP1是一种环状酸性蛋白,在真核生物进化过程中高度保守,广泛存在于机体各处。其经典亚细胞定位为线粒体,但也可见于细胞质、细胞核和细胞膜,并可被分泌,因此被视为多区室蛋白。p32可在不同亚细胞位置与多种生理功能各异的配体相互作用,并调节其功能。主要配体包括C1q、透明质酸、钙网蛋白、CD44、整合素、蛋白激酶C(PKC)、剪接因子ASF/SF2及多种微生物蛋白。p32参与线粒体代谢与动态变化、细胞凋亡、RNA剪接、免疫应答和炎症,并调节多条细胞信号通路。
值得注意的是,许多上皮肿瘤中p32过表达,且其表达水平与患者生存呈负相关。多项癌细胞功能获得和/或功能缺失研究表明,p32可促进恶性肿瘤特征,包括增殖、细胞存活、化疗耐药、血管生成、免疫调节、迁移、侵袭和转移。这些发现强烈提示,p32可能是癌症诊断分子和治疗靶点。事实上,以p32为靶点的治疗策略已取得临床前进展,包括肿瘤归巢肽、单克隆抗体、细胞内抑制剂、p32肽疫苗及p32 CAR-T 细胞。这些进展前景良好,有望推动p32不久后纳入靶向癌症治疗方案。
P32/gC1qR/HABP1 is a doughnut-shaped acidic protein, highly conserved in eukaryote evolution and ubiquitous in the organism. Although its canonical subcellular localization is the mitochondria, p32 can also be found in the cytosol, nucleus, cytoplasmic membrane, and it can be secreted.
Therefore, it is considered a multicompartmental protein. P32 can interact with many physiologically divergent ligands in each subcellular location and modulate their functions. The main ligands are C1q, hyaluronic acid, calreticulin, CD44, integrins, PKC, splicing factor ASF/SF2, and several microbial proteins. Among the functions in which p32 participates are mitochondrial metabolism and dynamics, apoptosis, splicing, immune response, inflammation, and modulates several cell signaling pathways.
Notably, p32 is overexpressed in a significant number of epithelial tumors, where its expression level negatively correlates with patient survival. Several studies of gain and/or loss of function in cancer cells have demonstrated that p32 is a promoter of malignant hallmarks such as proliferation, cell survival, chemoresistance, angiogenesis, immunoregulation, migration, invasion, and metastasis.
All of this strongly suggests that p32 is a potential diagnostic molecule and therapeutic target in cancer. Indeed, preclinical advances have been made in developing therapeutic strategies using p32 as a target. They include tumor homing peptides, monoclonal antibodies, an intracellular inhibitor, a p32 peptide vaccine, and p32 CAR T cells. These advances are promising and will allow soon to include p32 as part of targeted cancer therapies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。